Evotec, Harvard and Janssen Form Three-Way Collaboration in Beta Cell Regeneration
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 19 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1781 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Germany’s Evotec has licensed a portfolio of small molecules and biologics from its CureBeta regenerative diabetes collaboration with Harvard University and the Howard Hughes Medical Institute to Johnson & Johnson’s Janssen Pharmaceuticals subsidiary...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS